Stocks-NVAX-Novavax Inc

NVAX Novavax Inc

14.32 -0.35 (-2.39%)
Market OpenDelayed Prices By NASDAQ, in USD
Trade
Stocks-NVAX-Novavax Inc
NVAX Novavax Inc
Trade

Overview

Prev Close 14.68
Day's Range 13.99 - 14.65
52 Week Range 3.52 - 23.37
Average Volume (3M) 6.75M
1-Year Return 87.37%
Beta2.0596
Market Cap 2.35B
P/E Ratio-5.31
Revenue987.67M
EPS-2.7665
Dividend (Yield) 0 (0%)
Sector
Health Technology
Industry
Biotechnology
CEO
John C.s Jacobs, MBA
Employees
1,543

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2023: Novavax Inc's revenues decreased by 38.48% and amounted to 983.71M. Net income increased by 17.16% to -545.06M. Net assets decreased by 13.07% to -716.93M and EPS increased from -8.42 to -5.41.
NVAX's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Created with Highcharts 4.2.7 /Highstock 4.2.7Total RevenueNet Income09/2312/2303/2406/24-300M-200M-100M0100M200M300M400M500M
Gross Margin
66.32%
Net Profit Margin
-207.94%
Operating Margin
-28.95%
Return On Investment
-3,168.44%
09/23
12/23
03/24
06/24
Total Revenue
186.99M
291.34M
93.86M
415.48M
Gross Profit
88.06M
142.47M
34.65M
379.44M
Operating Income
-125.77M
-183.57M
-144.83M
162.12M
Net Income
-130.78M
-178.39M
-147.55M
162.38M